Early Growth Response Protein [Egr] Levels in Patients with Fibromyalgia Syndrome.
EGR1
EGR2
EGR3
Early Growth Response [EGR] proteins
Fibromyalgia syndrome
Protein levels
Journal
Protein and peptide letters
ISSN: 1875-5305
Titre abrégé: Protein Pept Lett
Pays: Netherlands
ID NLM: 9441434
Informations de publication
Date de publication:
24 Nov 2023
24 Nov 2023
Historique:
received:
05
04
2023
revised:
22
08
2023
accepted:
13
09
2023
medline:
27
11
2023
pubmed:
27
11
2023
entrez:
27
11
2023
Statut:
aheadofprint
Résumé
Fibromyalgia is a soft tissue rheumatism characterized by chronic and widespread musculoskeletal pain at specific points in the body. In this study, we aimed to investigate the relationship between Early Growth Response [EGR1, EGR2, and EGR3] protein levels in patients with Fibromyalgia Syndrome[FMS] and healthy controls. In our studies, 76 FMS patient group and 78 healthy control group who were newly diagnosed with primary FMS according to the 2010 American College of Rheumatology criteria for fibromyalgia in Sivas Cumhuriyet University Hospital, Physical Therapy, and Rehabilitation were used. Venous blood samples were taken from both groups for the measurement of EGR1, EGR2, and EGR3 protein plasma levels, and protein levels were determined using ELISA methods. Statistical parametric test assumptions were compared using the Independent Student's t-test. In addition, specificity, sensitivity, and AUC values were calculated with the ROC curve. The relationship between plasma EGR1 protein levels of FMS patients and control groups was statistically significant [p=0.001]. EGR1 protein levels were found to be lower in the patient group diagnosed with FMS compared to the control group. It has been suggested that EGR1 protein levels can be important in the diagnosis of FMS disease.
Sections du résumé
BACKGROUND
BACKGROUND
Fibromyalgia is a soft tissue rheumatism characterized by chronic and widespread musculoskeletal pain at specific points in the body.
OBJECTIVES
OBJECTIVE
In this study, we aimed to investigate the relationship between Early Growth Response [EGR1, EGR2, and EGR3] protein levels in patients with Fibromyalgia Syndrome[FMS] and healthy controls.
METHOD
METHODS
In our studies, 76 FMS patient group and 78 healthy control group who were newly diagnosed with primary FMS according to the 2010 American College of Rheumatology criteria for fibromyalgia in Sivas Cumhuriyet University Hospital, Physical Therapy, and Rehabilitation were used. Venous blood samples were taken from both groups for the measurement of EGR1, EGR2, and EGR3 protein plasma levels, and protein levels were determined using ELISA methods. Statistical parametric test assumptions were compared using the Independent Student's t-test. In addition, specificity, sensitivity, and AUC values were calculated with the ROC curve.
RESULTS
RESULTS
The relationship between plasma EGR1 protein levels of FMS patients and control groups was statistically significant [p=0.001].
CONCLUSION
CONCLUSIONS
EGR1 protein levels were found to be lower in the patient group diagnosed with FMS compared to the control group. It has been suggested that EGR1 protein levels can be important in the diagnosis of FMS disease.
Identifiants
pubmed: 38008944
pii: PPL-EPUB-136272
doi: 10.2174/0109298665256584231103113328
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.